依达拉奉联合奥拉西坦治疗对急性脑梗死患者炎性因子的影响
2020-12-23张文政徐西朋黄登学
张文政 徐西朋 黄登学


【摘要】 目的 觀察和探讨依达拉奉联合奥拉西坦对急性脑梗死患者的疗效及血清炎性因子的影响。方法 选取76例急性脑梗死患者作为研究对象, 根据治疗方法不同分为试验组和对照组, 每组38例。两组患者均给予抗感染、脑细胞保护、颅内压降低、血压控制等常规治疗, 对照组给予奥拉西坦治疗, 试验组在对照组基础上给予依达拉奉治疗。比较两组患者治疗效果;治疗前后炎性因子[血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平;治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、巴氏(Barthel)指数评分。结果 试验组患者总有效率94.74%(36/38)明显高于对照组的76.32%(29/38), 差异有统计学意义(P<0.05)。治疗前, 两组患者的TNF-α、IL-6水平比较, 差异均无统计学意义(P>0.05);治疗后, 试验组患者的TNF-α、IL-6水平均明显低于对照组, 差异具有统计学意义(P<0.05)。治疗前, 两组患者NIHSS评分、Barthel指数评分比较, 差异均无统计学意义(P>0.05);治疗后, 试验组NIHSS评分、Barthel指数评分均优于对照组, 差异具有统计学意义(P<0.05)。结论 依达拉奉联合奥拉西坦治疗急性脑梗死患者, 能够降低患者脑损伤, 同时使神经功能得到康复, 提高患者的日常生活活动能力, 可以在临床上进行推广应用。
【关键词】 依达拉奉;奥拉西坦;急性脑梗死;炎性因子
DOI:10.14163/j.cnki.11-5547/r.2020.31.038
Analysis on the effects of edaravone combined with oxiracetam on inflammatory factors in patients with acute cerebral infarction ZHANG Wen-zheng, XU Xi-peng, HUANG Deng-xue. Liangshan County Peoples Hospital, Jining 272600, China
【Abstract】 Objective To observe and discuss the efficacy of edaravone combined with oxiracetam on patients with acute cerebral infarction, and its impact on inflammatory factors. Methods A total of 76 patients with acute cerebral infarction as study subjects were divided into experimental group and control group, with 38 cases in each group. Both groups were treated with conventional treatments such as anti-infection, brain cell protection, intracranial pressure reduction, and blood pressure control. The control group was also treated with oxiracetam, and the experimental group was also treated with edaravone on the basis of the control group. The therapeutic effect, inflammatory factors [serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)] before and after treatment, National Institutes of Health stroke scale (NIHSS) score, Barthel index score before and after treatment were compared between the two groups. Results The total effective rate of the experimental group 94.74%(36/38) was obviously higher than that of the control group 76.32%(29/38), and the difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference in TNF-α and IL-6 level between the two groups (P>0.05). After treatment, TNF-α and IL-6 level of the experimental group was obviously lower than that of the control group, and the difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference in NIHSS score and Barthel index score (P>0.05). After treatment, NIHSS score and Barthel index score of the experimental group was better than that of the control group, and the difference was statistically significant (P<0.05). Conclusion The combination of edaravone and oxiracetam in the treatment of patients with acute cerebral infarction can reduce the patients brain injury, recover the neurological function, and improve the patients ability of daily living activities, which can be promoted and applied in clinical practice.
【Key words】 Edaravone; Oxiracetam; Acute cerebral infarction; Inflammatory factors
脑梗死即缺血性脑卒中, 认为是一种脑血管疾病, 其坏死、软化和梗死是由脑血供应中断引起的脑组织缺血和缺氧引起的[1]。临床主要表现为偏瘫和意识障碍, 临床上最常见的有脑血栓形成和脑栓塞。急性脑梗死的救治应积极防治并发症, 注重维护心肺功能, 保持呼吸道畅通, 保证血氧水平, 高度警惕心律失常、心肌梗死、心力衰竭的发生[2, 3]。急性脑梗死的治疗方法有药物治疗、介入治疗、手术治疗及早期康复治疗等[4]。本研究选取本院2019年1 月~2020年1 月收治的急性脑梗死患者76例作为研究对象进行研究, 现报告如下。……
